跳转至内容
Merck
CN
  • Evaluation of corneal changes after conventional versus accelerated corneal cross-linking: a randomized controlled trial.

Evaluation of corneal changes after conventional versus accelerated corneal cross-linking: a randomized controlled trial.

Journal of refractive surgery (Thorofare, N.J. : 1995) (2014-12-02)
Hesam Hashemian, Mahmoud Jabbarvand, Mehdi Khodaparast, Kambiz Ameli
摘要

To evaluate the outcome of accelerated and conventional corneal cross-linking (CXL) procedures regarding their effect on morphological and optical properties of the cornea. One hundred fifty-three eyes of 153 patients were evaluated before and during a 15-month follow-up period after CXL (76 eyes in the conventional group and 77 eyes in the accelerated group). Measured variables include corrected distance visual acuity (CDVA), uncorrected distance visual acuity (UDVA), refraction, maximum keratometry, endothelial cell density, anterior and posterior stromal keratocyte density, and subbasal nerve density. All variables were compared between the two study groups. Cylindrical and spherical components of refraction improved significantly during 15 months of follow-up. No difference was observed between the two study groups. UDVA and CDVA improved in the same manner, with no intergroup differences. Endothelial cell density did not change significantly during the follow-up period in either group. K-max increased slightly in the first month of the follow-up, but started to decrease at postoperative visits without any significant difference in the two groups. Anterior stromal keratocyte density and subbasal nerve density decreased significantly in both groups 1 month postoperatively. Both variables had a more significant decrease in the conventional group at all visits before the 1-year visit. At the final 15-month visit, there were no significant differences in any value between the two groups. Accelerated and conventional CXL seem to have a comparable and acceptable effect on keratoconus in the short-term follow-up period.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type IV, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
I型胶原蛋白 溶液 来源于大鼠尾, BioReagent, suitable for cell culture, sterile-filtered
Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type IV, powder
Sigma-Aldrich
胶原蛋白 来源于大鼠尾, Bornstein and Traub Type I, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
(−)-核黄素, from Eremothecium ashbyii, ≥98%
Supelco
核黄素 (B2), analytical standard
Sigma-Aldrich
(−)-核黄素, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Sigma-Aldrich
胶原蛋白 来源于鸡胸软骨, Type II (Miller), powder, BioReagent, suitable for cell culture
Sigma-Aldrich
胶原蛋白 来源于小牛皮, Bornstein and Traub Type I, (0.1% solution in 0.1 M acetic acid), aseptically processed, BioReagent, suitable for cell culture
Supelco
核黄素, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
胶原蛋白IV型 来源于人类细胞培养基, Bornstein and Traub Type IV, 0.3 mg/mL, sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type I (Sigma Type VIII), powder
Sigma-Aldrich
(−)-核黄素, meets USP testing specifications
USP
核黄素, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
胶原 人, Bornstein and Traub Type I, acid soluble, powder, ~95% (SDS-PAGE)
核黄素, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type III (Sigma Type X), powder
Sigma-Aldrich
胶原蛋白 来源于 Engelbreth-Holm-Swarm 小鼠肉瘤基底膜, Type IV (Miller), lyophilized powder, BioReagent, suitable for cell culture
Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type IV, solution, suitable for cell culture, High Performance
Sigma-Aldrich
胶原蛋白 来源于人类胎盘, Bornstein and Traub Type V (Sigma Type IX), powder
Sigma-Aldrich
胶原 来源于人类胎盘, Bornstein and Traub Type IV, powder
(−)-核黄素, European Pharmacopoeia (EP) Reference Standard